Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence.

"Disclosure of potential conflict of interest: A. Simpson reports lecture fees from Thermo Fisher Scientific. H. A. Brough reports advisory board work for DBV and research support from Thermo Fisher Scientific outside of the submitted work. A. Custovic reports personal fees from Novartis, Regeneron/Sanofi, Thermo Fisher Scientific, Boehringer Ingelheim, Novartis, and Philips outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest."

"Supported by UK Medical Research Council grants MR/K002449/1 and MR/LO12693/1. The Manchester Asthma and Allergy Study was supported by Asthma UK grants 301 (1995-1998), 362 (1998-2001), 01/012 (2001-2004), and 04/014 (2004-2007); the BMA James Trust (2005) and the JP Moulton Charitable Foundation (2004-current); the North West Lung Centre Charity (1997-current); and Medical Research Council grants G0601361 (2007-2012), MR/K002449/1 (2013-2014), and MR/L012693/1 (2014-2018). This report is independent research supported by the National Institute for Health Research (NIHR) South Manchester Respiratory and Allergy Clinical Research Facility at Manchester University NHS Foundation Trust (Wythenshawe) and by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. A.S. is supported by the Manchester Biomedical Research Centre."